Jinping Gan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5780622/publications.pdf

Version: 2024-02-01

54 papers	1,742 citations	279798 23 h-index	289244 40 g-index
55 all docs	55 docs citations	55 times ranked	2332 citing authors

#	Article	IF	Citations
1	Dansyl Glutathione as a Trapping Agent for the Quantitative Estimation and Identification of Reactive Metabolites. Chemical Research in Toxicology, 2005, 18, 896-903.	3.3	167
2	Synthesis and Biologic Evaluation of a Novel ¹⁸F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression. Journal of Nuclear Medicine, 2018, 59, 529-535.	5.0	152
3	Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban. Drug Metabolism and Disposition, 2013, 41, 827-835.	3.3	109
4	Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate, 2011, 71, 480-488.	2.3	101
5	In Vitro Screening of 50 Highly Prescribed Drugs for Thiol Adduct Formationâ€"Comparison of Potential for Drug-Induced Toxicity and Extent of Adduct Formation. Chemical Research in Toxicology, 2009, 22, 690-698.	3.3	96
6	Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry. Lab on A Chip, 2020, 20, 215-225.	6.0	84
7	Alkylaniline-Hemoglobin Adducts and Risk of Non-Smoking-Related Bladder Cancer. Journal of the National Cancer Institute, 2004, 96, 1425-1431.	6.3	72
8	Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. Experimental Biology and Medicine, 2017, 242, 1579-1585.	2.4	72
9	Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects. Drug Metabolism and Disposition, 2017, 45, 908-919.	3.3	67
10	Microphysiological systems for ADME-related applications: current status and recommendations for system development and characterization. Lab on A Chip, 2020, 20, 446-467.	6.0	66
11	Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2011, 17, 880-887.	7.0	42
12	Discovery and Validation of Pyridoxic Acid and Homovanillic Acid as Novel Endogenous Plasma Biomarkers of Organic Anion Transporter (OAT) 1 and OAT3 in Cynomolgus Monkeys. Drug Metabolism and Disposition, 2018, 46, 178-188.	3.3	40
13	Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 136-145.	2.5	38
14	Quantitative Analysis of Polyethylene Glycol (PEG) and PEGylated Proteins in Animal Tissues by LC-MS/MS Coupled with In-Source CID. Analytical Chemistry, 2014, 86, 7642-7649.	6.5	37
15	Drugâ€"Protein Adducts: Chemistry, Mechanisms of Toxicity, and Methods of Characterization. Chemical Research in Toxicology, 2016, 29, 2040-2057.	3.3	35
16	Ixabepilone, a Novel Microtubule-Targeting Agent for Breast Cancer, Is a Substrate for P-Glycoprotein (P-gp/MDR1/ABCB1) but not Breast Cancer Resistance Protein (BCRP/ABCG2). Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 423-432.	2.5	33
17	Repaglinideâ€gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. British Journal of Clinical Pharmacology, 2010, 70, 870-880.	2.4	32
18	Oxidation of 2,6-Dimethylaniline by Recombinant Human Cytochrome P450s and Human Liver Microsomes. Chemical Research in Toxicology, 2001, 14, 672-677.	3.3	31

#	Article	IF	Citations
19	InÂvitro model systems to investigate bile salt export pump (BSEP) activity and drug interactions: A review. Chemico-Biological Interactions, 2016, 255, 23-30.	4.0	29
20	Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors. Drug Metabolism and Disposition, 2010, 38, 1962-1966.	3.3	27
21	Discovery of ((S)-5-(Methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((i> As a Potent and Selective I_{Kur} Inhibitor. Journal of Medicinal Chemistry, 2012, 55, 3036-3048.	6.4	27
22	Non-cytochrome P450-mediated bioactivation and its toxicological relevance. Drug Metabolism Reviews, 2016, 48, 473-501.	3.6	26
23	Bioactivation of Substituted Thiophenes Including Î±-Chlorothiophene-Containing Compounds in Human Liver Microsomes. Chemical Research in Toxicology, 2011, 24, 663-669.	3.3	24
24	Cytochrome P450 11A1 Bioactivation of a Kinase Inhibitor in Rats: Use of Radioprofiling, Modulation of Metabolism, and Adrenocortical Cell Lines to Evaluate Adrenal Toxicity. Chemical Research in Toxicology, 2012, 25, 556-571.	3.3	23
25	Biotransformation Profiling of [14C]Ixabepilone in Human Plasma, Urine and Feces Samples Using Accelerator Mass Spectrometry (AMS). Drug Metabolism and Pharmacokinetics, 2009, 24, 511-522.	2.2	22
26	Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1128-1133.	2.2	19
27	Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents. European Journal of Pharmacology, 2005, 511, 31-41.	3.5	18
28	Discovery of Potent Heterodimeric Antagonists of Inhibitor of Apoptosis Proteins (IAPs) with Sustained Antitumor Activity. Journal of Medicinal Chemistry, 2015, 58, 1556-1562.	6.4	16
29	Biliary excretion of pravastatin and taurocholate in rats with bile salt export pump (Bsep) impairment. Biopharmaceutics and Drug Disposition, 2016, 37, 276-286.	1.9	16
30	Quantitation of repaglinide and metabolites in mouse whole-body thin tissue sections using droplet-based liquid microjunction surface sampling-high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. Journal of Chromatography A, 2016, 1439, 137-143.	3.7	16
31	Metabolism and Disposition of [¹⁴C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans. Drug Metabolism and Disposition, 2011, 39, 891-903.	3.3	15
32	Strategy for the Quantitation of a Protein Conjugate via Hybrid Immunocapture-Liquid Chromatography with Sequential HRMS and SRM-Based LC-MS/MS Analyses. Analytical Chemistry, 2017, 89, 5144-5151.	6.5	14
33	Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. Xenobiotica, 2010, 40, 138-145.	1.1	13
34	Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 330-335.	2.2	13
35	Tissue distribution and tumor uptake of folate receptorâ€“targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration. Acta Pharmaceutica Sinica B, 2016, 6, 460-467.	12.0	13
36	Enhanced and Persistent Inhibition of Organic Cation Transporter 1 Activity by Preincubation of Cyclosporine A. Drug Metabolism and Disposition, 2019, 47, 1352-1360.	3.3	13

#	Article	IF	Citations
37	CYP3A4-Mediated Ester Cleavage as the Major Metabolic Pathway of the Oral Taxane 3â€²-tert-Butyl-3â€²-N-tert-butyloxycarbonyl-4-deacetyl-3â€²-dephenyl-3â€²-N-debenzoyl-4-O-meth (BMS-275183). Drug Metabolism and Disposition, 2009, 37, 710-718.	3.3	12
38	Identification of the Oxidative and Conjugative Enzymes Involved in the Biotransformation of Brivanib. Drug Metabolism and Disposition, 2012, 40, 219-226.	3.3	12
39	Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3914-3919.	2.2	12
40	High-Resolution Mass Spectrometry-Based Background Subtraction for Identifying Protein Modifications in a Complex Biological System: Detection of Acetaminophen-Bound Microsomal Proteins Including Argininosuccinate Synthetase. Chemical Research in Toxicology, 2015, 28, 775-781.	3.3	11
41	Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11Î²â€hydroxysteroid dehydrogenase typeâ€1 inhibitor BMSâ€823778. British Journal of Clinical Pharmacology, 2018, 84, 130-141.	2.4	11
42	Development and characterization of rat duodenal organoids for ADME and toxicology applications. Toxicology, 2020, 446, 152614.	4.2	10
43	Bile Salt Homeostasis in Normal and Bsep Gene Knockout Rats with Single and Repeated Doses of Troglitazone. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 385-394.	2.5	9
44	Metabolic Chiral Inversion of Brivanib and Its Relevance to Safety and Pharmacology. Drug Metabolism and Disposition, 2012, 40, 2374-2380.	3.3	7
45	Hepatocyte spheroids as a viable in vitro model for recapitulation of complex in vivo metabolism pathways of loratadine in humans. Xenobiotica, 2020, 50, 621-629.	1.1	7
46	Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. Drug Metabolism and Disposition, 2020, 48, 724-734.	3.3	7
47	In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin. Cancer Chemotherapy and Pharmacology, 2012, 69, 51-56.	2.3	6
48	LCâ€“MS/MS bioanalysis of plasma 1, 14-tetradecanedioic acid and 1, 16-hexadecanedioic acid as candidate biomarkers for organic anion-transporting polypeptide mediated drugâ€“drug interactions. Bioanalysis, 2018, 10, 1473-1485.	1.5	5
49	Status and Future of 3D Cell Culture in Toxicity Testing. Methods in Pharmacology and Toxicology, 2018, , 249-261.	0.2	4
50	Ultrasensitive quantitative LCâ€“MS/MS of an inhibitor of apoptosis protein's antagonist in plasma using protein target affinity extraction. Bioanalysis, 2016, 8, 265-274.	1.5	3
51	Protocols for Assessment ofIn vitro andIn vivo Bioactivation Potential of Drug Candidates. , 0, , 447-476.		3
52	Troglitazone Thiol Adduct Formation in Human Liver Microsomes: Enzyme Knietics and Reaction Phenotyping. Drug Metabolism Letters, 2008, 2, 184-189.	0.8	2
53	Integration of Physiologicallyâ€Based Pharmacokinetic Modeling into Early Clinical Development: An Investigation of the Pharmacokinetic Nonlinearity. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 286-294.	2.5	2
54	Alternative Models in Biomedical Research: In Silico, InÂVitro, ExÂVivo, and Nontraditional InÂVivo Approaches. , 2022, , 925-966.		1